Longevica, a biotechnology company based in San Francisco, announced it is seeking $10 million to complete research focused on healthy aging and life extension. The funding will support final stages of preclinical and clinical studies exploring the potential of their proprietary compound aimed at delaying age-related diseases.
According to the company, their compound targets mechanisms associated with cellular health and longevity, with the goal of extending healthy lifespan. The company said it has already conducted initial safety and efficacy assessments and now plans to expand testing to broader cohorts.
Longevica claims it is collaborating with academic institutions and research partners to validate its findings. The planned studies include detailed analysis of biomarkers linked to aging and metabolic health, aiming to demonstrate the compound’s impact on key longevity pathways.
The company also announced ongoing development of an open research platform intended to share anonymized data and insights with scientists worldwide. According to Longevica, this initiative is part of its mission to accelerate scientific discovery in the longevity sector.
Longevica said it expects the new funding round to enable completion of required studies and support regulatory engagement for potential future clinical applications. The company stated that it remains committed to exploring interventions that could promote healthier and longer lives.
